BCRX

BioCryst Pharmaceuticals Inc

8.38

USD

BCRX Earnings Reports

Positive Surprise Ratio

BCRX beat 22 of 41 last estimates.

54%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

$154.70M

$0.05

Implied change from Q4 25 (Revenue/ EPS)

-4.85%

+400.00%

Implied change from Q1 25 (Revenue/ EPS)

+6.30%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On Feb 26, 2026, BCRX reported earnings of 0.01 USD per share (EPS) for Q4 25, missing the estimate of 0.03 USD, resulting in a -74.09% surprise. Revenue reached 162.57 million, compared to an expected 152.63 million, with a 6.51% difference. The market reacted with a -4.80% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 154.70 million USD, implying an increase of 400.00% EPS, and decrease of -4.85% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Guardian Pharmacy Services, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.25

Actual

$0.37

Surprise

+45.10%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.45

Actual

-$0.42

Surprise

+6.77%

Esperion Therapeutics, Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.24

Actual

$0.22

Surprise

-10.46%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Zevra Therapeutics, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

$0.05

Actual

$0.21

Surprise

+311.76%

SIGA Technologies Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

Actual

-$0.08

Surprise

Nature's Sunshine Products Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.19

Actual

$0.30

Surprise

+54.80%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.25

Surprise

+13.49%

Corbus Pharmaceuticals Holdings, Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$1.60

Actual

-$1.25

Surprise

+22.24%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.51

Surprise

+37.05%

FAQ

What were BioCryst Pharmaceuticals Inc's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, BioCryst Pharmaceuticals Inc reported EPS of $0.01, missing estimates by -74.09%, and revenue of $162.57M, 6.51% above expectations.

How did the market react to BioCryst Pharmaceuticals Inc's Q4 2025 earnings?

The stock price moved down -4.8%, changed from $7.09 before the earnings release to $6.75 the day after.

When is BioCryst Pharmaceuticals Inc expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for BioCryst Pharmaceuticals Inc's next earnings report?

Based on 6 analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.05 and revenue of $154.70M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.